The FDA approved UroGen Pharma’s intravesical hydrogel treatment, Zusduri (formerly UGN-102), for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer despite a narrowly negative advisory committee vote. The hydrogel allows nonsurgical treatment by delivering mitomycin directly into the bladder via catheter. Clinical trials showed 78% complete response at three months and a majority maintaining response at twelve months. The drug offers an alternative to repeated surgical resections which have high recurrence rates. UroGen plans US launch by July 1 and will submit ongoing postmarketing data as required by the FDA.